Gilead Sciences (GILD): Jefferies Positive On ASK1 PhII

November 15, 2016 7:59 AM EST
Get Alerts GILD Hot Sheet
Price: $71.57 --0%

Rating Summary:
    24 Buy, 11 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 28 | Down: 28 | New: 23
Trade GILD Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies analyst, Brian Abrahams, reiterated his Buy rating on shares of Gilead Sciences (NASDAQ: GILD) while attending AASLD, where detailed data from the positive ph.II study of ASK1 inhibitor '4997 were presented. While the small study and still evolving NASH diagnosis/treatment paradigm limit full assessment of ‘4997’s opportunity, overall the detailed data favorably answered several remaining outstanding questions and support the view--based on data analysis and prior KOL feedback--that ‘4997, like much of GILD’s pipeline, is underappreciated.

No change to the price target of $91.

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $76.75 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Management Comments

Related Entities

Jefferies & Co

Add Your Comment